Post My Press Release

Free Press Release Distribution

Category: Hospitals (Page 1 of 14)

Osseointegration Implants Market Is Expected To Have The Highest Growth Rate During The Forecast Period 2026

The Global Osseointegration Implants Market size was valued at US$ 5,672.3 million in 2017, and is projected to witness a CAGR of 6.72% over the forecast period (2018 – 2026).

Osseointegration is a process in which a bone anchorage is used on an implant surface which provides a basis to support a prosthesis till that part of the body becomes stronger and supports firmly. These implants are used in various applications such as dental implants, bone and joint replacement procedures, and implants undertaken for amputees. The osseointegration implants are made from material such as titanium, zirconia, ceramic, stainless steel, and others.

Increasing demand for osseointegration implants owing to rising number of joint replacement surgeries among geriatric population is expected to drive market growth. According to the Organisation for Economic Cooperation and Development (OECD), on an average, the rate of hip replacement has increased by 30% between 2000 and 2015, and the rate of knee replacement nearly doubled between 2000 and 2015. Moreover, average incidence of the Hip replacement surgery was 166 per 100,000 population in all 34 OECD countries in 2015.

Moreover, key players are opting for different strategies such as new product launch, acquisitions, partnerships, joint ventures, and agreements to increase their foothold in this market. For instance, in April 2018, Integrum SE launched a new revolutionary OPRA implant system, which will be initially available only in London and would be distributed through London International Patient Services (LIPS) – an organization seeking treatment for international patients.

Growing Number of Joint Replacement Surgeries Among Geriatric Population is Expected to Drive the Osseointegration Implants Market Revenue

Increasing patient population undergoing joint replacement surgeries has boosted growth of the global osseointegration implants market. According to the National Joint Registry (NJR), in 2017, around 992,090 primary total hip replacements, 1,087,611 knee replacements, 4,687 ankle replacements, 30,720 shoulder replacements, and 2,872 elbow replacements were performed in U.K. Moreover, in U.S, around 17,500 new Spinal Cord Injury (SCI) cases are performed annually and an estimated 285,000 people were suffering from SCI in 2017, as per National Spinal Cord Injury Statistical Center (NSCISC).

Increasing demand for cosmetic dentistry, owing to rising prevalence of dental decays is supporting growth of the global osseointegration implants market. According to the U.S. Department of Health and Human Services, the prevalence of total dental caries among the age group aged 2–19 years was 45.8% and it increases with age, from 21.4% (among age group 2–5) to 50.5% (among age group 6–11) and 53.8% (among age group 12–19) in 2016. Moreover, growing disposable incomes in various countries has also influenced growth of the osseointegration implants market.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2384

Osseointegration Implants Market Restraints

Although demand for osseointegration implants is increasing worldwide, high-cost associated with the implants or surgery with inadequate reimbursement coverage has restrained growth of the osseointegration implants market. In Australia, the surgical procedure to insert the implant is not covered by the Medicare system and is paid through self-funding or by an individual’s Private Health Insurance as per the Australian Orthotic Prosthetic Association. Moreover, risk and complications associated with osseointegration surgery is one of the major factor hampering growth of the market.

Osseointegration Implants Market – Competitive Landscape

Key players operating in the global osseointegration implants market include Medtronic, Stryker Corporation, Zimmer Biomet Holdings, Smith and Nephew Plc., Straumann AG Group, Integrum SE, Southern Implants, ConMed Corporation and others. Manufacturers in osseointegration implants market are focused on expanding their distribution channels in emerging economies, which offers untapped growth opportunities for the growth of the osseointegration implants market.

Osseointegration Implants Market – Regional Insights

On the basis of region, the global osseointegration implants market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold the leading position in the global osseointegration implants market by 2026, owing to well-established healthcare infrastructure, high adoption rate for technologically advanced products, and growing widespread awareness about minimally invasive surgeries. Moreover, high prevalence of degenerative spinal conditions are fueling growth of the market in this region.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market Trends Research And Projections For 2018-2026

The paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired bone marrow failure disorder, which leads to premature death and impaired red blood cells (RBCs). PNH is characterized by hemolytic anemia, thrombosis, and peripheral blood cytopenia. Mutation in the PIGA-A gene of hematopoietic stem cells causes deficiency of the two glycosylphosphatidylinositol (GPI) anchored proteins, namely CD55 and CD59 in the patient’s body, which gives rise to the premature destruction of RBCs. Click To Read More On Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market

Symptoms of paroxysmal nocturnal hemoglobinuria includes hemolytic anemia, hemoglobinuria, fatigue, breathlessness, abdominal pain, difficulty in controlling bleeding even from very minor wounds, appearance of small red dots on the skin that indicates bleeding under the skin, severe headache, and blood clots (thrombosis). Bone marrow transplant (stem cell transplant) is the only curative therapy for paroxysmal nocturnal hemoglobinuria available so far.

Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market: Drivers

The global paroxysmal nocturnal hemoglobinuria therapeutics market size is expected to witness significant growth over the forecast period, owing to increasing demand for PNH therapeutics and rising number of treatment approvals from the U.S. Food and Drug Administration (FDA) for PNH, which includes iron supplements, blood transfusion, blood thinner, Eculizumab (Soliris), and bone marrow transplant. According to a study published in Blood Journal in 2012, the 5 year survival-rate of patients treated with Soliris is 95.5%.

Moreover, new R&D studies are being conducted for development of cost-effective PNH treatment, which is expected to drive the paroxysmal nocturnal hemoglobinuria therapeutics market revenue. For instance, in 2014, the research team of Perelman School of Medicine at Pennsylvania, U.S. investigated a compound named PEG-Cp40, which is long-acting and cost-effective for the treatment of paroxysmal nocturnal hemoglobinuria.

Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market: Restraints

The paroxysmal nocturnal hemoglobinuria therapeutics market revenue is expected to hamper because of high cost for the treatment of paroxysmal nocturnal hemoglobinuria. For instance, in 2017, the American Council on Science and Health (ACSH) declared Eculizumab (Soliris) as the most expensive drug in the U.S. and cost of Solirirs ranges up to US$ 500,000 per person per year.

Moreover, the side effects shown by the drug Soliris such as headache, fatigue, nausea, vomiting, diarrhea, muscle pain, and nasal congestion can also negatively impact the paroxysmal nocturnal hemoglobinuria therapeutics market size. There are some serious side effects also, which includes low White Blood Cell (WBC) count, increased chances of bacterial infections such as meningitis, and bacterial sinusitis. According to the Centers for Disease Control and Prevention (CDC) reports of 2017, patients under the therapy of Eculizumab (Soliris) are at 1,000 to 2,000 times greater at risk of getting meningococcal diseases han the healthy individuals in the U.S.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2542

Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market: Competitive Landscape

Key players operating in the global paroxysmal nocturnal hemoglobinuria therapeutics market include Alexion Pharmaceuticals, Akari therapeutics, Apellis Pharmaceuticals, Amgen Inc, CinnaGen Co, Ra Pharmaceuticals Inc, Alnylam Pharmaceuticals, Achillion Pharmaceuticals Inc, Novartis, Roche, and Regeneron Pharmaceuticals.

Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market: Regional Analysis

North America is expected to dominate in paroxysmal nocturnal hemoglobinuria therapeutics market during the forecast period, owing to new approvals from the FDA. For instance, in 2018, Ravulizumab (Ultomiris) from Alexion Pharmaceuticals and APL2 from Apellis Pharmaceuticals was approved by the FDA, for the treatment of paroxysmal nocturnal hemoglobinuria.

Asia Pacific paroxysmal nocturnal hemoglobinuria therapeutics market size is expected to witness significant growth due to availability of cost-effective treatment and medical tourism for PNH. According to an article published by National Center for Biotechnology Information (NCBI) in 2014, the cost of bone marrow transplant in India was between US$ 10,000 and US$ 40,000 in 2014 and in the U.S., it was between US$ 73,000 and US$ 140,000 in 2012.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Cytotoxic Drugs Market Usage, Dosage And Side Effects Analysis 2018 to 2026

Cytotoxic drugs or cytostatics (cytotoxic chemotherapy) are agents used to destroy cancer cells and tumors by inhibiting cell division. These drugs are widely used as anti-cancer agents and are used to boost the outcomes of surgery or radiotherapy, reduce metastasis, and diminish cancer symptoms. Increasing use and approval of cytotoxic drugs is the major factor driving the cytotoxic drugs market growth. These drugs are also used for their immunosuppressive effect in the treatment of auto-immune conditions, rheumatoid arthritis, psoriasis, or prevention of transplant rejection. Click To Read More On Cytotoxic Drugs Market

Global Cytotoxic Drugs Market: Drivers

The cytotoxic drugs market size is expected to grow significantly during the forecast timeframe, owing to increasing incidences of cancer worldwide. According to World Health Organization’s (WHO) 2018 report, around 9.6 million deaths were recorded due to cancer and around 18.1 million new cases of cancer were diagnosed in 2018 worldwide.

Furthermore, increasing number of cytotoxic drug approvals is expected to boost the market growth. For instance, in November 2018, the U.S. FDA approved Pfizer’s DAURISMO (glasdegib) in the U.S. for adult patients with newly-diagnosed acute myeloid leukemia for whom intensive chemotherapy is not an option. Other potential factor that contributes to cytotoxic drugs market revenue growth is increasing therapeutic area of cytotoxic drugs in auto-immune conditions, rheumatoid arthritis, psoriasis, or prevention of transplant rejection because of its immunosuppressive or anti–proliferative effects.

Global Cytotoxic Drugs Market: Restraints

The major restraining factor for the cytotoxic drugs market growth is adverse side effects shown by consumption of cytotoxic drugs such as nausea and vomiting, severe diarrhea, and damage to bone marrow. Cytotoxic drugs can be toxic to other organ systems and lead to conditions such as gastrointestinal toxicity, neurotoxicity renal toxicity, and cardiovascular toxicity. For instance, according to NHS Lothian Joint Formulary, drugs such as fluorouracil, doxorubicin, and oral capecitabine may cause severe stomatitis, diarrhea, and coronary spasm mimicking angina. Moreover, systemic anti-cancer therapy (SACT) drugs increase the risk of thromboembolic disease eventually restraining the cytotoxic drugs market growth.

Global Cytotoxic Drugs Market: Competitive Landscape

Key players operating in the global cytotoxic drugs market include, Eli Lilly and Company, Sanofi S.A., F. Hoffmann-La Roche Ltd, Pfizer Inc., Celgene Corporation, Amgen Inc., Novartis AG Merck and Co., Johnson and Johnson, and GlaxoSmithKline Plc.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2533

Global Cytotoxic Drugs Market: Regional Analysis

North America is expected to hold a dominant position in the cytotoxic drugs market over the forecast period, owing to increasing awareness and availability of wide range of cytotoxic drugs in the region. According to a study published in National Center for Biotechnology Information (NCBI) in 2017, the U.S. Food and Drug Administration has approved 61 cytotoxic drugs for cancer, which help in increasing the survival rates of cancer patients.

Asia Pacific cytotoxic drugs market size is expected to witness significant growth, owing to large patient base and increasing healthcare insurance schemes in the region. For instance, in 2018, the Government of India launched Pradhan Mantri Jan Arogya Yojana (PMJAY) to provide health insurance worth US$ 7,124.54 to over 100 million families, annually.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Anticonvulsants Market To Witness Robust Expansion By 2026

Anticonvulsants are pharmaceutical agents used for the treatment of epileptic seizures. These are commonly known as anti-epileptic drugs or anti-seizure drugs. Epilepsy is a chronic central nervous system (neurological) disorder, wherein brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations, and sometimes loss of awareness. Anticonvulsant drugs are also used for the treatment of bipolar disorder, borderline personality disorder, fibromyalgia, and neuropathic pain. Epilepsy can affect any individual at any age. According to Epilepsy Society of U.K. 2019 data, over 20 drugs are available for the treatment of epilepsy such as barbiturates, carboxamides, carbamates, and GABA analogs and around 25 generics are present in the Anticonvulsants Market.

Global Anticonvulsants Market: Drivers

The anticonvulsants market size is expected to increase over the forecast period, owing to rising prevalence of epilepsy globally. According to the World Health Organization (WHO) January 2019 report, around 50 million people are affected by epilepsy worldwide. Moreover, it is estimated that around 2.4 million new cases of epilepsy are diagnosed every year, globally.

Increasing approval of anticonvulsant drugs from the U.S. Food and Drug Administration (FDA) are highly contributing to increase in the anticonvulsants market revenue. There are around 24 anticonvulsants drugs approved by the FDA. In 2018, FDA approved the first drug containing an active ingredient derived from marijuana to treat rare, severe forms of epilepsy such as Lennox-Gastaut syndrome and Dravet syndrome.

Global Anticonvulsants Market: Restraints

The side effects such as sores, blisters or ulcers in mouth, excessive bleeding in wounds, stomach pain and tenderness, fever, and unusual infections, of anticonvulsants drugs is a major restraining factor for anticonvulsants market growth. According to the Epilepsy Foundation report of 2013, there are some unpredictable side effects known as idiosyncratic side effects that can be fatal, which includes serious drop in the number of white blood cells and platelets in the body, Aplastic anemia, and liver failure.

Global Anticonvulsants Market: Competitive Landscape

Key players operating in the global anticonvulsants market include Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Novartis AG, Pfizer Inc., Valeant Pharmaceuticals International, Inc., Sanofi S.A., UCB Group, Shire Plc., GlaxoSmithKline Plc., Cephalon Inc., and Astrazeneca Plc.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2516

Global Anticonvulsants Market: Regional Analysis

North America is expected to hold dominant position in the anticonvulsants market during the forecast period, owing to increasing demand for treatment of epilepsy. For instance, according to the WHO 2019 report, in up to 70% of people living with epilepsy globally, seizure is controlled with appropriate diagnosis and use of anti-epileptic medicines. Low-cost treatment is available, with daily medication that costs US$ 5 per year.

Asia Pacific anticonvulsants market revenue is expected to witness significant growth over the forecast period, owing to increasing prevalence of epilepsy in economies such as India, China, and Japan. According to the National Center for Biotechnology Information 2015 report, India has huge patient base of 12 million people affected by epilepsy.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Saliva Collection Devices Market Positive Long-Term Growth Outlook 2018- 2026

The Global Saliva Collection Devices Market was valued at US$ 1,571.7 million in 2017, and is expected to witness a CAGR of 10.8% over the forecast period (2018 – 2026).

Saliva is the most favored sample of choice in diagnosis due to ease of collection. Salivary biomolecules have provided an aperture in surveying a person’s health and well-being. Saliva contains a myriad of salivary proteins, which could serve as biological markers for diagnosing and tracking the progression of various health conditions, as well as monitoring the effectiveness of medication. Saliva collection devices allow a person to collect resting (unstimulated) saliva or stimulated saliva either via mechanical stimulation or acid stimulation.

Market Dynamics

Rising research activities for saliva collection devices is expected to boost growth of the saliva collection devices in the market. For instance, in July 2017, EquiSal Tapeworm saliva test was launched in the U.S. for detecting tapeworms from saliva of horses. EquiSal saliva collection kits are used for saliva collection, which comprises swabs to be kept in oral cavity of horses.

Furthermore, new marketing strategies by key players are expected to drive growth of the saliva collection devices market over the forecast period. For instance, in October 2018, Mayo Clinic and Helix’s lab launched a solution called, Mayo Clinic GeneGuide. It allows shipment of saliva collection kits to the individual within two days and furthermore, DNA is sequenced for identifying diseases.

Increasing number of saliva collection device approvals is expected to drive growth of the saliva collection devices market

Increase in the number of approvals for saliva collection devices due to its rising need for rapid diagnosis of life threatening diseases is expected to drive growth of the saliva collection devices market. For instance, in February 2015, 23andMe, Inc., received U.S. Food and Drug Administration (USFDA) approval to market the first direct-to-consumer genetic Oragene Dx saliva collection test kits under a regulatory classification for novel devices. The company works with DNA Genotek, a subsidiary of OraSure Technologies, Inc, for Oragene Dx saliva collection kits. Saliva collected by these kits is then used to screen for Bloom Syndrome, a genetic disease.

Furthermore, in January 2015, DNA Genotek Inc., received USFDA approval for Oragene Dx intended for use in the non?invasive collection of saliva samples. DNA from the saliva sample is then isolated, stabilized, and legally marketed for DNA carrier screening genotyping tests.

Moreover, technological advancements for saliva collection of infants are also expected to increase growth of the saliva collection devices market. For instance, Oasis Diagnostics, developed Pedia SAL collection kit for infants. It allows saliva collection process with simplest design intended to not only collect saliva samples but also relax infants during procedure. Saliva can then be expressed from the collector using a compression tube directly into any of a variety of common laboratory vials.

Saliva Collection Devices Market- Competitive Landscape

Key players operating in the saliva collection devices market include Quest Diagnostics, Neogen Corporation, AboGen, Inc., OraSure Technologies, Inc., Oasis Diagnostics Corporation, Alere, Porex Corporation., and Salimetrics, LLC.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2523

Saliva Collection Devices Market- Regional Analysis

Regional segmentation of the global saliva collection devices market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America held the major share in the global saliva collection devices market during the forecast period, owing to increasing number of new and innovative product launches in the U.S. For instance, in June 2016, DNA Genotek launched saliva sample collection device ORAcollectDx, an alternative to buccal swabs. The device, ORAcollectDx, is part of saliva-based DNA collection and stabilization devices.

Asia Pacific is expected to witness the fastest growth in the global saliva collection devices market the forecast period, due to increasing awareness for safe and easy diagnosis of various diseases through number of symposiums and conferences organized in the region. For instance, in October 2016, Saliva Technology Application Research Symposium was held by Queensland University of Technology, in Australia. The conference highlighted emerging research, translational and technological advances such as saliva biomarker development, innovative saliva collection devices, improving saliva stability and transportation, rapid disease identification, saliva rheology, and many more.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Ureteroscopes Market Shows Expected Trend to Guide from 2018- 2026 with Growth Analysis

Ureteroscope is a device, which is used for examining upper urinary tract and the technique is called ureteroscopy. Ureteroscope works similar to a cytoscope, however, it is longer and thinner than cytoscope, and is passed through the urethra to the bladder and then into the ureter (the tubes, which carry urine from kidneys to bladder). Ureteroscope has illuminating light and lens for capturing images of urinary tract organs for presence of tumors and calculi. This device helps to find the position of stone in ureter and is also used for the removal of kidney stone. Click To Read More On Ureteroscopes Market.

Ureteroscopes Market Drivers

Increasing approvals and launches of new ureteroscopes devices is expected to be a major factor for growth of the global ureteroscopes market. For instance, in 2016, Boston Scientific Corporation launched its new LithoVue single-use digital flexible ureteroscope in the U.S. and Europe market. LithoVue is used in minimally invasive diagnosis and treatment of kidney stones and other conditions of the kidney, ureter, and bladder.

Furthermore, increasing prevalence of kidney stone is expected to increase demand for ureteroscopes and fuel the market growth. For instance, according to the data published by National Kidney Foundation in 2016, globally, over half a billion people suffer from kidney stone annually. According to data published by National Institute of Health, in 2016, globally, total prevalence of chronic kidney disease is around 14.0% of the general population.

Moreover, prevalence of kidney stones also increases with increasing age. According to the data published in National Center for Biotechnology Information, in 2017, in Mainland China the prevalence of kidney stone was 5.96% in the people aged between 30-39 years, while the prevalence was around 9.68% in people above 60 years of age. Hence, rise in geriatric population is also expected to increase incidence of kidney stone, which in turn is expected to increase demand for ureteroscopes and fuel market growth in the near future. For instance, according to the United Nations Economic and Social Commission for Asia and the Pacific (ESCAP) 2016, around 547 million people were aged above 60 years in Asia Pacific and the number is projected to reach around 1.3 billion by 2050.

Ureteroscopes Market Key Players

Key players operating in ureteroscopes market include Boston Scientific Corporation, Olympus Corporation, Stryker Corporation, KARL STORZ SE & Co. KG, Richard Wolf GmbH, PENTAX Medical, Elmed Electronics & Medical Industry & Trade Inc., AED.MD, SCHÖLLY FIBEROPTIC GMBH, OPCOM Inc., Prosurg, Inc., SOPRO-COMEG GmbH, and others.

Ureteroscopes Market Regional Analysis

North America is expected to hold the dominant position in global ureteroscopes market, due to presence of key players in the region and high success rates of ureteroscopy. For instance, according to data published by Department of Urology, New York Medical College, in 2016, after a single procedure, around 37% of patients who had undergone flexible ureteroscopy were stone free as compare to only 21% of the patients who were treated with Extracorporeal Shock Wave Lithotripsy (ESWL). Moreover, Boston Scientific Corporation and Stryker Corporation are the two U.S.-based major players in this market. Furthermore, increasing prevalence of kidney stone in the U.S. is also expected to increase demand for ureteroscopes, which is turn is driving the market growth in North America.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1603

For instance, according to data published in National Center for Biotechnology Information, in 2014, according to survey done by National Health and Nutrition Examination in 2012, around 10.6% of men and 7.1% of women in the U.S. are affected from renal stone disease and there is a rapid increase in prevalence of urinary tract stone disease. Asia Pacific is expected to exhibit significant growth in the global ureteroscopes market, owing to increasing incidence of kidney stone disease in population in India and China. For instance, according to data published in National Center for Biotechnology Information in 2017, the prevalence of kidney stone in Mainland China was estimated to be around 10.34% in males and 6.62% in females.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Genome Engineering Market to Perceive Substantial Growth During 2018–2026

The Global Genome Engineering Market was valued at US$ 2,582.7 Mn in 2016 and is expected to witness a CAGR of 14.3% over the forecast period (2017–2025).

Genome engineering is a technique in which a DNA is inserted, deleted, modified or replaced in the genome of a living organism. Research and development activities are conducted in genome engineering for the development of novel technologies. For instance, in 2017, Synthego Corporation launched a CRISPR Pioneers Program to expand genome engineering research. Researchers are majorly focusing on developing treatments for cancer and rare diseases with the help of genome engineering tools such as CRISPER. Many genome technologies are under trial for treatment of such diseases, and are expected to receive approvals in the near future.

Market Dynamics

Development of novel technologies in genome engineering field is expected to significantly drive growth of the global genome engineering market in the near future. For instance, in 2017, Merck KGaA— Germany-based company—developed a new genome editing tool dubbed ‘proxy-CRISPR’, providing access to previously inaccessible microenvironments of the genome by modification of chromatin modifications. In 2017, Benson Hill Biosystems, Inc.—an agricultural technology company—launched its latest CRISPR 3.0, to increase innovators’ access to gene editing. CRISPR 3.0 is a latest innovative genomics tool, which is expected to improve crop performance. Development of such novel technologies by major key players is expected to create a conducive environment for growth of market.

Increasing development of novel technologies in genome engineering is expected to drive growth of the global genome engineering market in the near future

Key players in the market are focusing on developing novel technologies and launching new products for genome engineering, in order to increase their market share. For instance, in February 2018, Sangamo Therapeutics, Inc. received clinical trial authorization (CTA) from Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. for its SB-FIX, a zinc finger nuclease (ZFN)-mediated in-vivo genome editing treatment for hemophilia B. CTA has allowed for the beginning of Europe’s first in-vivo genome editing study. In 2017, Integrated DNA Technologies, Inc. launched the first Cas9 enzyme variant, which reduces off-target effects in CRISPR genome editing.

The launch of latest Cas9 enzyme variant is a major step towards therapeutic use of CRISPR. In 2017, Scientists at Salk Institute for Biological Studies, modified CRISPR to epigenetically treat diabetes, kidney disease, and muscular dystrophy. They developed a latest version of CRISPR/Cas9 genome editing technology, which allows for activation of genes without creating breaks in the DNA. The development of such novel technologies is expected to be major driving factor for growth of global genome engineering market.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1262

Increasing strategic collaboration for genome engineering technologies by key players is expected to drive market growth in the near future

Players in the market are focusing on strategic collaborations, in order to increase their product offerings. For instance, in February 2018, Kite Pharma, Inc.—a Gilead Sciences, Inc. company— collaborated with Sangamo Therapeutics Inc. for developing engineered cell therapies to treat cancer. As per the agreement, Kite Pharma, Inc. will use Sangamo Therapeutics’ zinc finger nuclease (ZFN) gene-editing technology for developing next-generation ex vivo cell therapies for treatment of cancer. Furthermore, in 2017, Synthego and Thermo Fisher Scientific collaborated to manufacture and distribute synthetic guide RNA products for CRISPR genome engineering. In 2016, CRISPR Therapeutics and Bayer AG collaborated and formed a joint venture Casebia Therapeutics, for developing CRISPR-based therapeutics in select disease areas. Moreover, in 2017, Casebia Therapeutics collaborated with CureVac AG.

Competitive Landscape

Key players operating in the genome engineering market include Thermo Fisher Scientific Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Editas Medicine, Inc., Sangamo Therapeutics, Inc., Bluebird Bio, Inc., Cellectis S.A., and Merck Group.

Moreover, increasing funding and investments for the development and research of new genetic engineering technologies is also expected to drive market growth. For instance, in January 2018, the U.S. National Institutes of Health (NIH) announced to grant US$ 190 million for genome editing research. This new program, Somatic Cell Genome Editing, will award funds to biomedical researchers over the following six years. The support from major research organizations such as NIH is expected to attract more researchers in this field, which may lead to advancements in technology and also aid in growth of the market.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Saline Laxatives Market Predicted to Grow at a Moderate Pace Through 2026

The Global Saline Laxatives Market size was valued at US$ 317.7 million in 2018, and is expected to witness a CAGR of 6.9% over the forecast period (2018 – 2026).

Saline laxatives are used to treat constipation or to cleanse the colon in preparation for a colonoscopy. Saline laxative work by absorbing water into the intestine, which softens the stool. These drugs rapidly increase the frequency of complete bowel actions, reduce constipation-associated symptoms and improve disease-related quality of life. Mild saline laxatives such as milk of magnesia and oral magnesium hydroxide have been used to treat constipation during pregnancy.

Market Dynamics

Increasing number of constipation incidences coupled with rising geriatric population base worldwide is the major factor driving the saline laxatives market growth. Low fluid and fibre diet intake may also play a major role in onset of constipation. According to the AGA Journal 2011 data, constipation affects 12% to 19% of Americans every year; its prevalence increases with age and it affects women more than men. Constipation causes psychological impairment, social distress, sexual dysfunction, altered interpersonal relationship, and impairment in quality of life. It has a major impact on social and economic burden. As per U.S. FDA, Americans spend more than US$ 700 million annually on over-the-counter laxatives.

Constipation during pregnancy is a common problem. According to the BMC journal 2012 data, the reported prevalence of constipation in pregnant women varies between 11 to 38% and occurs mostly during the third trimester, although symptoms can be present from 12 weeks gestation. However, most obstetricians advise avoiding laxatives during pregnancy and prescribe stool softeners instead due to its potential side effects.

Increasing prevalence of chronic constipation is expected to drive the saline laxatives market growth

Increasing prevalence of constipation coupled with sedentary lifestyle, consumption of low fluid and fiber diet and rising geriatric population are major factors expected to drive the global saline laxative market growth. According to a National Center for Biotechnology Information (NCBI) study 2016, chronic constipation is a common complaint encountered by both gastroenterologists and primary care physicians, with prevalence estimates ranging from 1% to 8% among the North American population. Moreover, constipation occurs more frequently in women, with a female/male ratio ranging from 1.01 to 3.77.

The burden of chronic constipation also affects work productivity, employment, and social activities. According to the Canadian Journal of Gastroenterology and Hepatology 2007 study, among patients suffering from chronic constipation, 30% believe that they were less productive at work or at school, 13% missed work or school days, and nearly 10% were late or had to leave work or school due to their symptoms. Therefore, demand for saline laxatives is significantly boosting with increasing cases of chronic constipation.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2195

Competitive Analysis

Key players operating in the global saline laxatives market include Beutlich Pharmaceuticals LLC, Bayer AG, C.B. Fleet Company, Inc., Salix Pharmaceuticals, Safeway Inc., Supervalu Inc., The Kroger Company, and Walgreen Co.

Saline Laxatives Market – Regional Insights

On the basis of region, the global saline laxatives market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America saline laxative market is expected to foresee increase in revenue share, owing to increasing constipation related emergency in regional hospitals. For instance, according to a study published in a journal in 2015, national cost of constipation-related emergency department visits in the U.S. increased by 121.4% from 723,886,977 in 2006 to 1.6 billion in 2011.

Europe saline laxative market is anticipated to grow at significant rate, owing to increasing spending over the use of laxatives. For instance, according to the Health and Social Care Information Centre, in 2013, in the UK more than 17 million laxative items were prescribed. According to a study published by a journal, in Norway, a population of around 5.2 million, spent US$ 22.1 million in 2014, on laxatives.

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Page 1 of 14

Powered by WordPress & Theme by Anders Norén